Literature DB >> 7078426

Effects of interruption of the enterohepatic circulation of bile acids on the transport of very low density-lipoprotein triglycerides.

U Beil, J R Crouse, K Einarsson, S M Grundy.   

Abstract

An increase in plasma very low density lipoprotein-triglycerides (VLDL-TG) is seen frequently during treatment with bile acid-binding resins. The purpose of this study was to determine whether this increment in VLDL-TG is due mainly to an increase in synthesis of VLDL, or to an enhanced catabolism. Three types of patients were studied: (1) 7 normotriglyceridemic subjects. (2) 4 obese patients, and (3) 9 hypertriglyceridemic patients. Before treatment they underwent a study of VLDL-TG kinetics that employed multicompartmental analysis of specific activity curves following injection of 3H-glycerol. The patients were then treated with a bile acid-binding resin, either cholestyramine or colestipol, for several weeks to several months. At the end of the treatment period, they were readmitted to the hospital for a second study of VLDL-TG kinetics. The patients showed a variable response to resin therapy. Many had an increase in concentrations of VLDL-TG, but others had no change or even a slight decrease. However, analysis of the data showed a high correlation between change in production rates of VLDL-TG and change in concentration. Also, when the data for the 20 patients were combined, there was a statistically significant increase in both synthetic rates and concentrations of VLDL-TG; in contrast, the fractional catabolic rate (FCR) was unchanged by therapy. Therefore, our data show that when treatment with bile acid sequestrants causes an increase in plasma VLDL-TG, the increase is due to an increment in production and not to a decrease in catabolism.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7078426     DOI: 10.1016/0026-0495(82)90231-1

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  27 in total

Review 1.  Human CYP7A1 deficiency: progress and enigmas.

Authors:  Anne Beigneux; Alan F Hofmann; Stephen G Young
Journal:  J Clin Invest       Date:  2002-07       Impact factor: 14.808

Review 2.  A comparative review of the adverse effects of treatments for hyperlipidaemia.

Authors:  A Steiner; B Weisser; W Vetter
Journal:  Drug Saf       Date:  1991 Mar-Apr       Impact factor: 5.606

Review 3.  Dyslipidemia in patients with chronic and end-stage kidney disease.

Authors:  Jad Omran; Ashraf Al-Dadah; Kevin C Dellsperger
Journal:  Cardiorenal Med       Date:  2013-07-13       Impact factor: 2.041

4.  Impaired absorption of cholesterol and bile acids in patients with an ileoanal anastomosis.

Authors:  K Hakala; M Vuoristo; P Luukkonen; H J Järvinen; T A Miettinen
Journal:  Gut       Date:  1997-12       Impact factor: 23.059

5.  Mechanisms of triglyceride metabolism in patients with bile acid diarrhea.

Authors:  Nidhi Midhu Sagar; Michael McFarlane; Chuka Nwokolo; Karna Dev Bardhan; Ramesh Pulendran Arasaradnam
Journal:  World J Gastroenterol       Date:  2016-08-14       Impact factor: 5.742

6.  Bile acid metabolism in hereditary forms of hypertriglyceridemia: evidence for an increased synthesis rate in monogenic familial hypertriglyceridemia.

Authors:  B Angelin; K S Hershon; J D Brunzell
Journal:  Proc Natl Acad Sci U S A       Date:  1987-08       Impact factor: 11.205

7.  Different patterns of postprandial lipoprotein metabolism in normal, type IIa, type III, and type IV hyperlipoproteinemic individuals. Effects of treatment with cholestyramine and gemfibrozil.

Authors:  M S Weintraub; S Eisenberg; J L Breslow
Journal:  J Clin Invest       Date:  1987-04       Impact factor: 14.808

8.  Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c.

Authors:  Mitsuhiro Watanabe; Sander M Houten; Li Wang; Antonio Moschetta; David J Mangelsdorf; Richard A Heyman; David D Moore; Johan Auwerx
Journal:  J Clin Invest       Date:  2004-05       Impact factor: 14.808

9.  Physical activity as a determinant of fecal bile acid levels.

Authors:  Betsy C Wertheim; María Elena Martínez; Erin L Ashbeck; Denise J Roe; Elizabeth T Jacobs; David S Alberts; Patricia A Thompson
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-04-21       Impact factor: 4.254

10.  Dual actions of fibroblast growth factor 19 on lipid metabolism.

Authors:  Xinle Wu; Hongfei Ge; Hélène Baribault; Jamila Gupte; Jennifer Weiszmann; Bryan Lemon; Jonitha Gardner; Preston Fordstrom; Jie Tang; Mingyue Zhou; Minghan Wang; Yang Li
Journal:  J Lipid Res       Date:  2012-12-02       Impact factor: 5.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.